Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 276 of the 277 references it cites were found in a registry or an index; 180 of the 297 sources its claims cite were checked for support.

Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan

Open access
Lee, Angel A., Den Hartigh, Laura J. · 2025 · Frontiers in Endocrinology

Abstract

The aged population, expected to double by 2050, makes up a large proportion of people living with metabolic disease. Obesity rates in the elderly are rapidly increasing, with estimates that nearly 40% of men and women over the age of 60 are classified as obese. White adipose tissue (WAT) is a highly metabolically active organ that undergoes significant changes during both obesity and aging, and metabolic dysfunction in WAT is a major cause for elevated diabetes risk. A marked difference in fat distribution is often reported between men and women. Many studies suggest that pre-menopausal women are protected from the accumulation of visceral adiposity due to gonadal estrogen, which exerts cardiometabolic benefits. Men with obesity harbor a disproportionately higher volume of intra-abdominal fat than premenopausal age-matched women with obesity, an effect that is negated by menopause as women begin to gain intra-abdominal fat. Post-menopausal women are at increased risk of developing diabetes, which can be mitigated by estrogen replacement therapy, suggesting an important role for sex steroids in diabetes risk. In addition to being highly responsive to gonadal estrogens, WAT has the capacity to convert androgens into estrogens, which may similarly impact WAT distribution and metabolism. Estrogens, comprised primarily of estrone (E1) and estradiol (E2) within WAT, are biosynthesized from circulating androgens androstenedione (A4) and testosterone (T) by aromatase (CYP19A1), which is highly expressed in human and mouse adipose tissue. In post-menopausal women, WAT becomes the predominant source of estrogen production, with age-associated increases in WAT aromatase expression that are mirrored by obesity. In contrast to ovarian estrogen production, in which E2 is the predominant estrogen type, E1 tends to be the predominant estrogen post-menopause. To date, little is known about WAT-derived estrogens and their impact on metabolic health, but emerging evidence suggests that increased E1 levels may contribute to metabolic dysfunction in aging. This review will introduce known sex differences in adipose metabolism associated with aging, obesity, and diabetes, and discuss the impact of WAT-derived sex hormones on local and systemic metabolism.

Overview

CoChat Summary

TL;DR

This narrative review argues that white adipose tissue (WAT) is an active site of estrogen biosynthesis via aromatase and that locally produced estrogens—especially the postmenopausal shift toward estrone—may influence fat distribution, inflammation, and insulin resistance in sex-, age-, and depot-dependent ways. It synthesizes human observational and rodent evidence but concludes that the direct metabolic roles of WAT-derived estrogens, particularly E1, remain incompletely understood.

Key findings

  • WAT expresses aromatase (CYP19A1) and converts androgens to estrogens; after menopause WAT becomes the predominant estrogen source, with E1 rather than E2 dominating. In premenopausal women, WAT E1 concentrations were reported as 5–10 times higher in subcutaneous and visceral adipose tissue than serum, and aromatase expression correlated with VAT E1.
  • Estrogen effects appear depot- and receptor-dependent: E2/ERα generally promotes subcutaneous lipid storage and insulin sensitivity, whereas E1 associates positively with BMI, waist circumference, and adiposity and, in postmenopausal women, inversely with adiponectin and insulin sensitivity. In obese mice, E1 produced a pro-inflammatory phenotype while E2 was anti-inflammatory.
  • Metabolic risk shifts with menopause and aging: postmenopausal women face a five times greater risk of central obesity; an estimated 37.5% of men and 39.4% of women over age 60 in the United States are classified as obese; and T2D prevalence was estimated at 13% in men vs. 11% in women aged 20–79 in 2016.
  • Menopausal hormone therapy findings are mixed: the Nurses’ Health Study (n=21,028) reported a 20% reduced diabetes risk in MHT users, and the PEPI trial showed improved fasting glucose and insulin, but benefits may depend on timing and delivery route. SHBG is inversely associated with insulin resistance/T2D, yet mouse overexpression studies conflict—no protection over 4.5 months of high-fat diet vs. protection over 8 weeks.

Methods

  • Narrative review, not a systematic review or meta-analysis; it synthesizes human observational studies across the lifespan and preclinical rodent models.
  • Covers adipocyte metabolism in healthy, aging, obese, and diabetic states; estrogen receptor biology; depot-specific aromatase activity and estrogen conversion; and menopausal hormone therapy.
  • No primary data collection, systematic search strategy, or quantitative synthesis is described.

Limitations

  • Stated in the paper: little is known about WAT-derived estrogens and their metabolic impact; the role of E1 in WAT function and energy metabolism remains much less understood; and whether E1 has direct metabolic effects or acts through local conversion to E2 is unclear.
  • Stated in the paper: cross-sectional studies are limited in design; the SHBG–adiposity relationship is inconsistent, including a longitudinal finding that higher baseline SHBG may predict greater intra-abdominal adipose tissue gain, challenging cross-sectional results; MHT trials have mostly been in normal-weight women with modest reported effects; and no randomized controlled trials have directly examined metabolic impacts of oral vs. transdermal MHT.
  • Evident from the text: as a narrative review, it reports no systematic search, inclusion criteria, risk-of-bias assessment, or quantitative synthesis, and conclusions rely on heterogeneous observational and rodent studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2025.1682231

Cites

276 of 277 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (A) Fat distribution changes across the age span in women and men. Premenopausal women tend to store most fat in subcutaneous depots. After menopause, more fat accumulates in the visceral compartment, including ectopic fat surrounding the heart and in the liver. Young and older men tend to accumulate most of their fat in the intra-abdominal region, with more visceral and ectopic fat accumulation as they age. (B) Estrogen synthesis pathways in subcutaneous inguinal white adipose tissue (IWAT) and visceral gonadal white adipose tissue (GWAT). In both IWAT and GWAT, estrogens can be converted from androstenedione and/or testosterone due to the presence of aromatase (Cyp19a1). DHEA, androstenedione, androstenediol, and testosterone enter WAT from the circulation. Estrone (E1) results from androstenedione conversion, while estradiol (E2) is a product of testosterone conversion by aromatase. E1 and E2 can interconvert due to the action of 17-beta hydroxysteroid dehydrogenases 1 and 2 (Hsd17β1 and Hsd17β2). Aromatase expression and activity tends to be higher in IWAT. Created in BioRender. Lee, (A) (2025) https://BioRender.com/62mlzmg.
Figure 1 (A) Fat distribution changes across the age span in women and men. Premenopausal women tend to store most fat in subcutaneous depots. After menopause, more fat accumulates in the visceral compartment, including ectopic fat surrounding the heart and in the liver. Young and older men tend to accumulate most of their fat in the intra-abdominal region, with more visceral and ectopic fat accumulation as they age. (B) Estrogen synthesis pathways in subcutaneous inguinal white adipose tissue (IWAT) and visceral gonadal white adipose tissue (GWAT). In both IWAT and GWAT, estrogens can be converted from androstenedione and/or testosterone due to the presence of aromatase (Cyp19a1). DHEA, androstenedione, androstenediol, and testosterone enter WAT from the circulation. Estrone (E1) results from androstenedione conversion, while estradiol (E2) is a product of testosterone conversion by aromatase. E1 and E2 can interconvert due to the action of 17-beta hydroxysteroid dehydrogenases 1 and 2 (Hsd17β1 and Hsd17β2). Aromatase expression and activity tends to be higher in IWAT. Created in BioRender. Lee, (A) (2025) https://BioRender.com/62mlzmg.CC BY · PubMed Central
Figure 2 Schematic for estrogen synthesis pathways derived from cholesterol involving gonads (testes and ovaries), adrenal gland, and adipose tissue. Box 1: Gonadal and adrenal sex hormone synthesis pathways. Circulating cholesterol is transported across the mitochondrial membrane by steroidogenic acute regulatory protein (StAR) and CYP11A1 and is eventually converted to dehydroepiandrosterone (DHEA) via CYP17a1. In both testes and ovaries, DHEA is converted to androstenedione (A4) and testosterone (T) by HSD3b1 and HSD17b3, respectively. When aromatase (CYP19a1) is present, A4 and T are converted into estrone (E1) and estradiol (E2), respectively. Functional gonads release high levels of T from testes, and E2 from ovaries. Like the gonads, the adrenal gland can convert circulating cholesterol to androgens, primarily A4. Box 2: Adipose tissue androgen conversion pathways from healthy young people (left) and those with obesity, insulin resistance, PCOS, and/or advanced age (right). In people with robust gonadal function, circulating androgens (A4, T) are converted to E2 due to aromatase activity in white adipose tissue (WAT). Some E2 will convert to E1 due to HSD17b1 activity. In people with reduced gonadal function (i.e. advanced age, obesity, PCOS, and/or insulin resistance), the major circulating androgen is A4, which predominantly converts to E1 in WAT. Created in BioRender. Den Hartigh, L. (2025) https://BioRender.com/oqv7exy.
Figure 2 Schematic for estrogen synthesis pathways derived from cholesterol involving gonads (testes and ovaries), adrenal gland, and adipose tissue. Box 1: Gonadal and adrenal sex hormone synthesis pathways. Circulating cholesterol is transported across the mitochondrial membrane by steroidogenic acute regulatory protein (StAR) and CYP11A1 and is eventually converted to dehydroepiandrosterone (DHEA) via CYP17a1. In both testes and ovaries, DHEA is converted to androstenedione (A4) and testosterone (T) by HSD3b1 and HSD17b3, respectively. When aromatase (CYP19a1) is present, A4 and T are converted into estrone (E1) and estradiol (E2), respectively. Functional gonads release high levels of T from testes, and E2 from ovaries. Like the gonads, the adrenal gland can convert circulating cholesterol to androgens, primarily A4. Box 2: Adipose tissue androgen conversion pathways from healthy young people (left) and those with obesity, insulin resistance, PCOS, and/or advanced age (right). In people with robust gonadal function, circulating androgens (A4, T) are converted to E2 due to aromatase activity in white adipose tissue (WAT). Some E2 will convert to E1 due to HSD17b1 activity. In people with reduced gonadal function (i.e. advanced age, obesity, PCOS, and/or insulin resistance), the major circulating androgen is A4, which predominantly converts to E1 in WAT. Created in BioRender. Den Hartigh, L. (2025) https://BioRender.com/oqv7exy.CC BY · PubMed Central

Verification

Claims the paper makes

120 Valid · 6 Not valid · 40 Not checked · 17 Own results and interpretations

79 more claims · 56 with their cited sources checked

Create a free account to see all 183 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 84

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 274 references

Cited by

See all 32

Metadata

Authors
Lee, A. A., & Den Hartigh, L. J.
Affiliations
University of Washington (US)
Venue
Frontiers in Endocrinology
Published
2025-10-17
Volume
16
Pages
1682231-1682231
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4415303743
Cited by
32
References
274
Citations by year
2026: 31 · 2025: 1
FWCI
4.88
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
white adipose tissue, aromatase, estrone, estradiol, menopause, sex differences, aging, obesity, visceral fat, intra-abdominal fat, diabetes risk, androgen to estrogen conversion, estrogen replacement therapy
MeSH terms
Adipose Tissue, Aging, Animals, Estrogens, Female, Humans, Longevity, Male, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan. https://app.cochat.ai/papers/10.3389/fendo.2025.1682231
The paper
Lee, A. A., & Den Hartigh, L. J. (2025). Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1682231

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.